NeOnc Sets Nov. 17 FDA End-of-Phase 1 Meeting for Brain Cancer Candidate NEO212
核心洞察
NeOnc Technologies will meet the FDA on Nov. 17, 2026, for an in-person End-of-Phase 1 Type B meeting on its oral CNS cancer candidate NEO212.
The company will seek agency feedback on patient population, trial design, endpoints, dose selection and evidence needed for a future marketing application.
Phase 1 dose escalation was stopped after a dose-limiting toxicity at 810 mg, and 610 mg once daily on Days 1-5 of a 28-day cycle was chosen as the recommended Phase 2 dose.
NeOnc Technologies Holdings (搜索) has scheduled an in-person End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration for Nov. 17, 2026, to discuss the clinical development program for NEO212, its investigational oral therapy for central nervous system cancers. The meeting will take place at the FDA's White Oak campus in Silver Spring, Maryland.
The company said it plans to seek FDA feedback on an update to its proposed patient population, trial design, endpoints, dose selection and the evidence needed to support a future marketing application. NeOnc noted that scheduling the meeting does not establish FDA agreement on a trial design, an accelerated approval pathway or eventual approval of NEO212.
The meeting follows completion of the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 trial. In September 2025, the FDA authorized NeOnc to proceed with the Phase 2a and Phase 2b portions of that study.
Dose Selection and Phase 1 Findings
NeOnc previously reported that dose escalation was discontinued after a dose-limiting toxicity at 810 mg, given once daily on Days 1 through 5 of a 28-day cycle. The company selected 610 mg as the recommended Phase 2 dose.
The company also reported clinical activity during the Phase 1 portion. In one patient with recurrent IDH1 (搜索) wild-type, MGMT (搜索)-methylated glioblastoma (搜索), treatment with NEO212 produced a partial response with an approximately 60% reduction in tumor size, followed by prolonged disease control lasting 21 treatment months. NeOnc described that duration of disease control as notable in recurrent GBM, where outcomes after recurrence have historically been limited.
In a second patient with lung cancer (搜索) metastatic to the brain who had progressed after multiple lines of therapy, including immune checkpoint inhibitors, NEO212 was associated with stable disease lasting approximately 16 months. NeOnc characterized patients with brain metastases (搜索) from lung cancer who have progressed after multiple prior systemic therapies as a population with substantial unmet medical need and historically limited treatment options.
The company stated that these individual patient outcomes do not establish efficacy and require confirmation in larger studies. It said the durability of responses observed in Phase 1, together with the established recommended Phase 2 dose, provides the clinical rationale for further evaluation of NEO212 in the Phase 2 portions of NEO212-01.
Regulatory Strategy
Building on the Phase 1 findings, NeOnc intends to discuss its potential registrational development strategy and to seek FDA feedback on whether a proposed trial design could support a potential accelerated approval pathway.
"We have completed dose escalation and selected a recommended Phase 2 dose for NEO212," said Amir Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. "This meeting will help us understand FDA's feedback on the population, study design and endpoints for the next stage of development. We may update our plans after evaluating the agency's feedback."
Drug and Disease Context
NEO212 is an investigational oral conjugate of temozolomide and NEO100. It is being studied in CNS cancers, including recurrent glioblastoma (搜索). Preclinical studies support further evaluation of its potential activity and delivery characteristics, though clinical efficacy and safety have not been established. The candidate is being developed under an FDA investigational new drug application.
High-grade gliomas, including glioblastoma (搜索), are serious brain cancers with substantial unmet medical need. Treatment may include surgery, radiation and drug therapy, but recurrence is common.
NeOnc is a clinical-stage biopharmaceutical company developing therapies for CNS cancers. Its investigational programs include intranasal NEO100 and oral NEO212. Neither product is approved by the FDA for commercial use. The company has licensed intellectual property from the University of Southern California relating to its development programs.